FULCRUM THERAPEUTICS INC (FULC) Stock Income Statement
NASDAQ:FULC - Nasdaq - US3596161097 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 80.00M | 2.81M | 6.34M | 19.16M | 8.82M | |||
| Operating Expenses | 99.83M | 113.47M | 118.47M | 100.22M | 80.43M | |||
| Research and Development | 63.39M | 71.80M | 76.78M | 69.70M | 59.04M | |||
| Selling, General, and Administrative Expenses | 36.45M | 41.67M | 41.69M | 30.52M | 21.39M | |||
| Operating Income | -19.83M | -110.66M | -112.13M | -81.05M | -71.61M | |||
| Interest Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Other Income/Expense | 12.17M | 13.33M | 2.69M | 210.00K | 790.00K | |||
| Non Recurring Items | -2.06M | 0.00 | -430.00K | N/A | N/A | |||
| Income Before Taxes | -9.72M | -97.33M | -109.87M | -80.85M | -70.82M | |||
| Net Income | -9.72M | -97.33M | -109.87M | -80.85M | -70.82M | |||
| EBITDA | -18.24M | -108.49M | -109.72M | -78.53M | -69.23M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.16 | -1.59 | -2.44 | -2.29 | -2.79 | |||
| Non GAAP EPS | -0.22 | -1.58 | -2.48 | -2.29 | -2.81 | |||
| Statistics | ||||||||
| Profit Margin | -12.16% | -3470.05% | -1732.97% | -421.97% | -802.95% | |||
| Operating Profit Margin | -24.79% | -3945.24% | -1768.61% | -423.02% | -811.90% | |||
All data in USD